Document Detail


Recent developments in the treatment of hypertriglyceridemia.
MedLine Citation:
PMID:  11122689     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hypertriglyceridemia is now recognized as an independent risk factor of coronary artery disease (CAD). A recent secondary prevention study of CAD with a statin suggested that it may be prudent to target fasting triglycerides to less than 150 mg/dL. Secondary prevention trials of CAD with drugs acting primarily on triglycerides (fibrates) have shown that reducing triglycerides and increasing high-density lipoprotein (HDL) cholesterol, without significantly affecting low-density lipoprotein cholesterol slows down coronary artery luminal narrowing (Lopid Coronary Angiography Trial [LOCAT], Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT], Bezafibrate Infarction Prevention [BIP]). Furthermore, Veterans Administration-HDL Intervention Trial (VA-HIT) and Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 (GISSI) studies recently showed that gemfibrozil and fish oils, respectively, decreased CAD mortality in secondary prevention trials. Statins are also capable of significantly reducing high triglyceride levels. Further clinical studies are necessary to confirm in terms of mortality the beneficial effect of reducing triglycerides and increasing high-density lipoprotein cholesterol in secondary CAD prevention; whereas, in primary prevention the beneficial effect of drastically reducing triglycerides by the way of pharmacology needs to be proved.
Authors:
P Duriez; J C Fruchart
Related Documents :
20562079 - Familial hypercholesterolaemic downsized pig with human-like coronary atherosclerosis: ...
18198239 - Potential use of statins to prevent atrial fibrillation after coronary artery bypass su...
12397569 - Low serum total cholesterol is associated with marked increase in mortality in advanced...
8280789 - Increased oxidizability of plasma low density lipoprotein from patients with coronary a...
9550499 - Cholesterol lowering in the management of coronary artery disease: the clinical implica...
11070569 - The role of statins in acute coronary syndromes: managing the unmet need.
15476569 - Constrictive pericarditis versus restrictive cardiomyopathy: challenges in diagnosis an...
21075869 - Cardiac inflammation contributes to changes in the extracellular matrix in patients wit...
7095879 - The influence of hemodialysis fistulas on circulatory dynamics and left ventricular fun...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current atherosclerosis reports     Volume:  1     ISSN:  1523-3804     ISO Abbreviation:  Curr Atheroscler Rep     Publication Date:  1999 Jul 
Date Detail:
Created Date:  2001-01-26     Completed Date:  2001-07-05     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  100897685     Medline TA:  Curr Atheroscler Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  31-7     Citation Subset:  IM    
Affiliation:
Département d'Athérosclérose - U325 INSERM, Institut Pasteur et Faculté de Pharmacie, Université de Lille II, 1 rue du Professeur Calmette, 59019 Lille cedex, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antilipemic Agents / therapeutic use*
Bezafibrate / therapeutic use
Cholesterol, HDL / blood
Cholesterol, LDL / blood
Coronary Disease / etiology,  prevention & control
Fatty Acids, Omega-3 / therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Hypertriglyceridemia / blood,  complications,  drug therapy*
Chemical
Reg. No./Substance:
0/Antilipemic Agents; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Fatty Acids, Omega-3; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 41859-67-0/Bezafibrate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  New developments in the treatment of low high-density lipoprotein cholesterol.
Next Document:  The Air Force/Texas Coronary Atherosclerosis Prevention Study: implications for preventive cardiolog...